About
Technology
Issues
FAQ
Links
Official Page
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.